Sumitomo Pharma America, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 627
- Registration Number
- NCT00667407
Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 486
- Registration Number
- NCT00667797
Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 257
- Registration Number
- NCT00665600
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 629
- Registration Number
- NCT00641745
- Locations
- 🇺🇸
K&S Professional Research Services LLC, Little Rock, Arkansas, United States
🇺🇸Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸Fidelity Clinical Research Inc., North Miami, Florida, United States
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 456
- Registration Number
- NCT00616655
- Locations
- 🇺🇸
Southwestern Research, Inc., Pasadena, California, United States
🇺🇸Excell Research, Oceanside, California, United States
🇺🇸California Clinical Trials Medical Group, Paramount, California, United States
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT00615433
- Locations
- 🇺🇸
Lousiana Clinical Research, LLC, Shreveport, Louisiana, United States
🇺🇸UCSD Medical Center, San Diego, California, United States
🇺🇸Clinical Pharmacological Studies, Inc., Cerritos, California, United States
Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-01-02
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00583986
A Safety, Efficacy and Tolerability Study of SEP-225289
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-01-02
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 523
- Registration Number
- NCT00584974
A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects
- First Posted Date
- 2008-01-02
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00583947
Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00571428
© Copyright 2024. All Rights Reserved by MedPath